Literature DB >> 28600947

Incidence and mortality of pancreatic cancer on a rapid rise in Taiwan, 1999-2012.

Chao-Ming Tseng1, Shih-Pei Huang2, Wei-Chih Liao3, Chun-Ju Chiang4, Ya-Wen Yang4, Chi-Yang Chang5, Yao-Chun Hsu6, Hui-Chi Chen7, Han-Sun Chiang8, Jaw-Town Lin9.   

Abstract

BACKGROUND: Accumulating data has revealed a rapidly rising incidence of pancreatic cancer in Western countries, but convincing evidence from the East remains sparse. We aimed to quantify how the incidence and mortality rates of pancreatic malignancy changed over time in Taiwan, and to develop future projection for the next decade.
METHODS: This nationwide population-based study analyzed the Taiwan National Cancer Registry and the National Cause of Death Registry to calculate the annual incidence and mortality rates of pancreatic malignancy from 1999 to 2012 in this country. The secular trend of the incidence was also examined by data from the National Health Insurance Research Database.
RESULTS: A total of 21,986 incident cases of pancreatic cancer and 20,720 related deaths occurred during the study period. The age-standardized incidence rate increased from 3.7 per 100,000 in 1999 to 5.0 per 100,000 in 2012, with a significant rising trend (P<0.01). The increase was nationwide, consistently across subgroups stratified by age, gender, geographic region, and urbanization. Data from the National Health Insurance Research Database corroborated the rise of incident pancreatic cancer. Mortality also increased with time, with the age-standardized rate rising from 3.5 per 100,000 in 1999 to 4.1 per 100,000 in 2012 (P<0.01). In accordance with the incidence, the mortality trend was consistent in all subgroups. Both the incidence and mortality were projected to further increase by approximately 20% from 2012 to 2027.
CONCLUSION: The incidence and mortality of pancreatic cancer have been rapidly rising and presumably will continue to rise in Taiwan.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; National Health Insurance database; Pancreatic cancer; Secular trend

Mesh:

Year:  2017        PMID: 28600947     DOI: 10.1016/j.canep.2017.05.011

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  6 in total

1.  Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan.

Authors:  Hsiang-Lan Lai; Yen-Yang Chen; Chang-Hsien Lu; Chia-Yen Hung; Yung-Chia Kuo; Jen-Shi Chen; Hung-Chih Hsu; Ping-Tsung Chen; Pei-Hung Chang; Yu-Shin Hung; Wen-Chi Chou
Journal:  Cancer Med       Date:  2019-04-18       Impact factor: 4.452

2.  Epidemiology and risk factors of pancreatic cancer.

Authors:  Mario Capasso; Marilisa Franceschi; Kryssia Isabel Rodriguez-Castro; Pellegrino Crafa; Ginevra Cambiè; Chiara Miraglia; Alberto Barchi; Antonio Nouvenne; Gioacchino Leandro; Tiziana Meschi; Gian Luigi De' Angelis; Francesco Di Mario
Journal:  Acta Biomed       Date:  2018-12-17

3.  Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer.

Authors:  Shu-Hui Lee; Pei-Hung Chang; Ping-Tsung Chen; Chang-Hsien Lu; Yu-Shin Hung; Ngan-Ming Tsang; Chia-Yen Hung; Jen-Shi Chen; Hung-Chih Hsu; Yen-Yang Chen; Wen-Chi Chou
Journal:  Cancer Med       Date:  2019-05-17       Impact factor: 4.452

4.  A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer.

Authors:  Ji Min Park; Chen-Zou Mau; Yang-Ching Chen; Yen-Hao Su; Hsin-An Chen; Shih-Yi Huang; Jung-Su Chang; Ching-Feng Chiu
Journal:  Sci Rep       Date:  2021-10-28       Impact factor: 4.379

5.  Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.

Authors:  Lung-Hung Tsai; Kai-Wen Hsu; Cheng-Ming Chiang; Hsiu-Ju Yang; Yu-Huei Liu; Shun-Fa Yang; Pei-Hua Peng; Wei-Chung Cheng; Heng-Hsiung Wu
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

6.  Silencing NEDD9 by lentivirus-delivered shRNA inhibits the growth of BxPC-3 cells in vitro and in vivo.

Authors:  Tielong Wu; Yuanyuan Dai; Lili Xue; Yingyue Sheng; Yao Zhong; Yuzheng Xue
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.